Cargando…
Serum vascular endothelial growth factor is a potential biomarker for acute mountain sickness
Background: Acute mountain sickness (AMS) is the most common disease caused by hypobaric hypoxia (HH) in high-altitude (HA) associated with high mortality when progressing to high-altitude pulmonary edema (HAPE) and/or high-altitude cerebral edema (HACE). There is evidence for a role of pro- and ant...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10098311/ https://www.ncbi.nlm.nih.gov/pubmed/37064896 http://dx.doi.org/10.3389/fphys.2023.1083808 |
_version_ | 1785024779260002304 |
---|---|
author | Nourkami-Tutdibi, Nasenien Küllmer, Jennifer Dietrich, Sven Monz, Dominik Zemlin, Michael Tutdibi, Erol |
author_facet | Nourkami-Tutdibi, Nasenien Küllmer, Jennifer Dietrich, Sven Monz, Dominik Zemlin, Michael Tutdibi, Erol |
author_sort | Nourkami-Tutdibi, Nasenien |
collection | PubMed |
description | Background: Acute mountain sickness (AMS) is the most common disease caused by hypobaric hypoxia (HH) in high-altitude (HA) associated with high mortality when progressing to high-altitude pulmonary edema (HAPE) and/or high-altitude cerebral edema (HACE). There is evidence for a role of pro- and anti-inflammatory cytokines in development of AMS, but biological pathways and molecular mechanisms underlying AMS remain elusive. We aimed to measure changes in blood cytokine levels and their possible association with the development of AMS. Method: 15 healthy mountaineers were included into this prospective clinical trial. All participants underwent baseline normoxic testing with venous EDTA blood sampling at the Bangor University in United Kingdom (69 m). The participants started from Beni at an altitude of 869 m and trekked same routes in four groups the Dhaulagiri circuit in the Nepali Himalaya. Trekking a 14-day route, the mountaineers reached the final HA of 5,050 m at the Hidden Valley Base Camp (HVBC). Venous EDTA blood sampling was performed after active ascent to HA the following morning after arrival at 5,050 m (HVBC). A panel of 21 cytokines, chemokines and growth factors were assessed using Luminex system (IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p40, IL-1ra, sIL-2Rα, IFN-γ, TNF-α, MCP-1, MIP-1α, MIP-1β, IP-10, G-CSF, GM-CSF, EGF, FGF-2, VEGF, and TGF-β1). Results: There was a significant main effect for the gradual ascent from sea-level (SL) to HA on nearly all cytokines. Serum levels for TNF-α, sIL-2Rα, G-CSF, VEGF, EGF, TGF-β1, IL-8, MCP-1, MIP-1β, and IP-10 were significantly increased at HA compared to SL, whereas levels for IFN-γ and MIP-1α were significantly decreased. Serum VEGF was higher in AMS susceptible versus AMS resistant subjects (p < 0.027, main effect of AMS) and increased after ascent to HA in both AMS groups (p < 0.011, main effect of HA). Serum VEGF increased more from SL values in the AMS susceptible group than in the AMS resistant group (p < 0.049, interaction effect). Conclusion: Cytokine concentrations are significantly altered in HA. Within short interval after ascent, cytokine concentrations in HH normalize to values at SL. VEGF is significantly increased in mountaineers suffering from AMS, indicating its potential role as a biomarker for AMS. |
format | Online Article Text |
id | pubmed-10098311 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-100983112023-04-14 Serum vascular endothelial growth factor is a potential biomarker for acute mountain sickness Nourkami-Tutdibi, Nasenien Küllmer, Jennifer Dietrich, Sven Monz, Dominik Zemlin, Michael Tutdibi, Erol Front Physiol Physiology Background: Acute mountain sickness (AMS) is the most common disease caused by hypobaric hypoxia (HH) in high-altitude (HA) associated with high mortality when progressing to high-altitude pulmonary edema (HAPE) and/or high-altitude cerebral edema (HACE). There is evidence for a role of pro- and anti-inflammatory cytokines in development of AMS, but biological pathways and molecular mechanisms underlying AMS remain elusive. We aimed to measure changes in blood cytokine levels and their possible association with the development of AMS. Method: 15 healthy mountaineers were included into this prospective clinical trial. All participants underwent baseline normoxic testing with venous EDTA blood sampling at the Bangor University in United Kingdom (69 m). The participants started from Beni at an altitude of 869 m and trekked same routes in four groups the Dhaulagiri circuit in the Nepali Himalaya. Trekking a 14-day route, the mountaineers reached the final HA of 5,050 m at the Hidden Valley Base Camp (HVBC). Venous EDTA blood sampling was performed after active ascent to HA the following morning after arrival at 5,050 m (HVBC). A panel of 21 cytokines, chemokines and growth factors were assessed using Luminex system (IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p40, IL-1ra, sIL-2Rα, IFN-γ, TNF-α, MCP-1, MIP-1α, MIP-1β, IP-10, G-CSF, GM-CSF, EGF, FGF-2, VEGF, and TGF-β1). Results: There was a significant main effect for the gradual ascent from sea-level (SL) to HA on nearly all cytokines. Serum levels for TNF-α, sIL-2Rα, G-CSF, VEGF, EGF, TGF-β1, IL-8, MCP-1, MIP-1β, and IP-10 were significantly increased at HA compared to SL, whereas levels for IFN-γ and MIP-1α were significantly decreased. Serum VEGF was higher in AMS susceptible versus AMS resistant subjects (p < 0.027, main effect of AMS) and increased after ascent to HA in both AMS groups (p < 0.011, main effect of HA). Serum VEGF increased more from SL values in the AMS susceptible group than in the AMS resistant group (p < 0.049, interaction effect). Conclusion: Cytokine concentrations are significantly altered in HA. Within short interval after ascent, cytokine concentrations in HH normalize to values at SL. VEGF is significantly increased in mountaineers suffering from AMS, indicating its potential role as a biomarker for AMS. Frontiers Media S.A. 2023-03-30 /pmc/articles/PMC10098311/ /pubmed/37064896 http://dx.doi.org/10.3389/fphys.2023.1083808 Text en Copyright © 2023 Nourkami-Tutdibi, Küllmer, Dietrich, Monz, Zemlin and Tutdibi. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Physiology Nourkami-Tutdibi, Nasenien Küllmer, Jennifer Dietrich, Sven Monz, Dominik Zemlin, Michael Tutdibi, Erol Serum vascular endothelial growth factor is a potential biomarker for acute mountain sickness |
title | Serum vascular endothelial growth factor is a potential biomarker for acute mountain sickness |
title_full | Serum vascular endothelial growth factor is a potential biomarker for acute mountain sickness |
title_fullStr | Serum vascular endothelial growth factor is a potential biomarker for acute mountain sickness |
title_full_unstemmed | Serum vascular endothelial growth factor is a potential biomarker for acute mountain sickness |
title_short | Serum vascular endothelial growth factor is a potential biomarker for acute mountain sickness |
title_sort | serum vascular endothelial growth factor is a potential biomarker for acute mountain sickness |
topic | Physiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10098311/ https://www.ncbi.nlm.nih.gov/pubmed/37064896 http://dx.doi.org/10.3389/fphys.2023.1083808 |
work_keys_str_mv | AT nourkamitutdibinasenien serumvascularendothelialgrowthfactorisapotentialbiomarkerforacutemountainsickness AT kullmerjennifer serumvascularendothelialgrowthfactorisapotentialbiomarkerforacutemountainsickness AT dietrichsven serumvascularendothelialgrowthfactorisapotentialbiomarkerforacutemountainsickness AT monzdominik serumvascularendothelialgrowthfactorisapotentialbiomarkerforacutemountainsickness AT zemlinmichael serumvascularendothelialgrowthfactorisapotentialbiomarkerforacutemountainsickness AT tutdibierol serumvascularendothelialgrowthfactorisapotentialbiomarkerforacutemountainsickness |